drug
AUBAGIO
updated 5mo agoby Sanofi-Aventis US LLC
community read0 votes
🐶 often sniffed alongside
top 7- tagApproval56 co-mentions · 14 sources
- drugteriflunomide29 co-mentions · 15 sources
- company$SNYSanofi28 co-mentions · 14 sources
- company$SNYNFSanofi28 co-mentions · 14 sources
- tagSmall Molecule28 co-mentions · 14 sources
- companyGlenmark Pharmaceuticals Ltd3 co-mentions · 1 sources
- tagRecall1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying AUBAGIO
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
- phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- phase3Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- phase3Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- phase3A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
- phase4Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
News(4)
- FDA starts review of Roche’s multiple sclerosis pillThe FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.biopharma_dive · 3d ago
- Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battleNovartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche's own BTK inhibitor fenebrutinib.biospace · 1mo ago
- Novartis says MS pill succeeds in two large studiesNotably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.biopharma_dive · 1mo ago
- Merck adds to pharma’s AI push; Roche details MS drug resultsMerck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…biopharma_dive · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that